HMH Maestro

Leadership Announcements

HMH Administers Treatment to 1,000th Patient in COVID-19 Clinical Trials

All Locations

What you need to know

Hackensack Meridian Health has treated 1,000 patients in it’s COVID-19 clinical trials.

From antiviral drugs to immunotherapies, to the potential treatment properties of antibodies in the blood of COVID-19 survivors, the patients have been treated over the course of 10 clinical trials, as well as through compassionate use and expanded use access. The trials include treatments from major pharmaceutical companies as well as investigator-initiated research aimed at turning the tide against the coronavirus pandemic.

At Hackensack Meridian Health, the number of patients receiving access to these latest treatments is expected to grow with enrollments in the coming days and weeks.

Clinical Trials

The trials include:

The trials have specific criteria, following various guidelines at different phases of the investigational process, and are under the guidance of the Hackensack Meridian Health Office of Research Administration, which set up a research committee in the earliest days of the pandemic.

More information

For more information on the ORA, reach out to Cheryl Fittizzi, vice president of Research and Regulatory Affairs, at cheryl.fittizzi@hackensackmeridian.org.